Matthew Robert Cohen
Plus aucun poste en cours
Profil
Matthew Robert Cohen served as Corporate Secretary, General Counsel & SVP at GenMark Diagnostics, Inc. from 2011 to 2012.
He also worked as General Counsel at Inhibrx LP.
Cohen received his undergraduate degree from Emory University and his graduate degree from Washington School of Law.
Anciens postes connus de Matthew Robert Cohen
| Sociétés | Poste | Fin |
|---|---|---|
Inhibrx LP
 Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Conseiller Juridique Général | - |
| GENMARK DIAGNOSTICS, INC. | Conseiller Juridique Général | - |
Formation de Matthew Robert Cohen
| Emory University | Undergraduate Degree |
| Washington School of Law | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
GenMark Diagnostics, Inc.
 GenMark Diagnostics, Inc. Medical SpecialtiesHealth Technology GenMark Diagnostics, Inc. engages in the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its solutions include ePlex System and XT-8 System. The company was founded by Jon Faiz Kayyem in 1993 and is headquartered in Carlsbad, CA. | Health Technology |
Inhibrx LP
Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Health Technology |
